JP2004501204A5 - - Google Patents

Download PDF

Info

Publication number
JP2004501204A5
JP2004501204A5 JP2002505026A JP2002505026A JP2004501204A5 JP 2004501204 A5 JP2004501204 A5 JP 2004501204A5 JP 2002505026 A JP2002505026 A JP 2002505026A JP 2002505026 A JP2002505026 A JP 2002505026A JP 2004501204 A5 JP2004501204 A5 JP 2004501204A5
Authority
JP
Japan
Prior art keywords
antibody
peptide
tyrosine
antibody fragment
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002505026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501204A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2001/000786 external-priority patent/WO2002000245A1/en
Publication of JP2004501204A publication Critical patent/JP2004501204A/ja
Publication of JP2004501204A5 publication Critical patent/JP2004501204A5/ja
Pending legal-status Critical Current

Links

JP2002505026A 2000-06-28 2001-06-28 神経毒オリゴマー Pending JP2004501204A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21477900P 2000-06-28 2000-06-28
US24217700P 2000-10-23 2000-10-23
PCT/AU2001/000786 WO2002000245A1 (en) 2000-06-28 2001-06-28 Neurotoxic oligomers

Publications (2)

Publication Number Publication Date
JP2004501204A JP2004501204A (ja) 2004-01-15
JP2004501204A5 true JP2004501204A5 (cg-RX-API-DMAC7.html) 2009-12-17

Family

ID=26909346

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002505026A Pending JP2004501204A (ja) 2000-06-28 2001-06-28 神経毒オリゴマー

Country Status (10)

Country Link
US (2) US7618634B2 (cg-RX-API-DMAC7.html)
EP (1) EP1296705B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004501204A (cg-RX-API-DMAC7.html)
CN (2) CN1450908A (cg-RX-API-DMAC7.html)
AU (2) AU6882801A (cg-RX-API-DMAC7.html)
CA (1) CA2413354C (cg-RX-API-DMAC7.html)
DK (1) DK1296705T3 (cg-RX-API-DMAC7.html)
ES (1) ES2389811T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ523428A (cg-RX-API-DMAC7.html)
WO (1) WO2002000245A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7955812B2 (en) 2004-07-19 2011-06-07 The General Hospital Corporation Methods of diagnosing alzheimer's disease by detecting antibodies to cross-linked β-amyloid oligomers
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
WO2007089335A2 (en) * 2005-12-29 2007-08-09 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2009048631A1 (en) * 2007-10-11 2009-04-16 University Of Tennessee Research Foundation PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP2013511734A (ja) * 2009-11-24 2013-04-04 プロビオドルグ エージー アルツハイマー病又は軽度認知障害の診断のための新規診断方法
WO2011106732A1 (en) 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN112352170B (zh) * 2018-05-15 2024-08-23 鲍希与洛姆伯股份有限公司 可水提取的眼用装置
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
DE102019129221B4 (de) 2019-10-29 2022-05-12 Chiracon Gmbh Verfahren zur Synthese von DOPA mit einer fotolabilen Schutzgruppe und Zwischenprodukten zu dessen Herstellung
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
KR20230128606A (ko) * 2022-02-28 2023-09-05 경상국립대학교산학협력단 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물
CN117024554A (zh) * 2023-05-30 2023-11-10 中国人民解放军空军军医大学 一种Aβ1-42寡聚体存储液的制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Similar Documents

Publication Publication Date Title
US8318171B2 (en) Neurotoxic oligomers
CA2501945A1 (en) Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
Feldman et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer
WO2003000714A3 (en) Compositions and methods for preventing protein aggregation in neurodegenerative diseases
JP2002533680A5 (cg-RX-API-DMAC7.html)
AU2011281247B2 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
WO2002096350A3 (en) Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
JP2005500389A5 (cg-RX-API-DMAC7.html)
AU2001268828A1 (en) Neurotoxic oligomers
EP2027874A3 (en) Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
RU2001130068A (ru) Антиидиотипические антитела к антителам, которые ингибируют связывание иммуноглобулина с его высокоаффинным рецептором
Kou et al. Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease
CN119504936A (zh) 赖氨酸l-苯乳酸化修饰半抗原、人工抗原及其制备方法和应用
CN119504937A (zh) 赖氨酸苯乙酰化修饰半抗原、人工抗原及其制备方法和应用
Bearn et al. The impact of naloxone/lofexidine combination treatment on the opiate withdrawal syndrome
RU2353389C2 (ru) Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций
CA2468496A1 (en) Ilk inhibitors for the treatment of renal disease
CN119504938A (zh) 赖氨酸2-羟基苯乙酰化修饰半抗原、人工抗原及其制备方法和应用
RU2007145527A (ru) Применение связывания антитело-лиганд для описания заболевания
WO2003034977A3 (en) Combination therapy for treating disease
HK1131745B (en) Neurotoxic oligomers
Genetet et al. ELSA PTH: A new immunoradiometric assay for the determination of the intact human parathormone
HK1015796A (en) Novel antibody, renin-active substance containing the same and prorenin assay using the same
JP2001081041A (ja) 非特異的IgE産生促進剤